FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
Published: | Updated:
FDA clears hands-free on-body injector for isatuximab in multiple myeloma, cutting treatment time and reactions while matching IV efficacy.
August 2026
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL
3
FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer
4
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
5